Pregabalin and Gabapentin for Neuropathic Pain and Fibromyalgia

Efficacy and Pharmacokinetics

Both pregabalin and gabapentin are effective for neuropathic pain and fibromyalgia, with small to moderate improvements in pain scores, and are recommended by the Centers for Disease Control and Prevention (CDC) 1
Pregabalin provides faster pain relief (within 1.5-3.5 days) compared to gabapentin, which requires 2+ months for adequate therapeutic trial, as suggested by the American Academy of Neurology 2
Both achieve 32-38% of patients with at least 50% pain reduction versus 17-21% with placebo, according to the National Institute of Neurological Disorders and Stroke 2

Pregabalin's target therapeutic dose is 300 mg/day (150 mg BID or 100 mg TID) within 1 week, as recommended by the American College of Physicians 2
Gabapentin's target therapeutic dose is 1800-3600 mg/day in three divided doses, with a titration period of 3-8 weeks, as suggested by the American Academy of Family Physicians 3, 4

Both require mandatory dose reduction based on creatinine clearance, as both are eliminated primarily unchanged by renal excretion, according to the National Kidney Foundation 2, 3
Elderly patients require lower starting doses and slower titration due to increased fall risk from dizziness and confusion, as recommended by the American Geriatrics Society 2, 3

Both cause dizziness, somnolence, peripheral edema, and weight gain, with side effects being dose-dependent and typically mild to moderate, according to the FDA 1, 2
Gabapentin demonstrated superior tolerability with fewer treatment discontinuations, as suggested by the American College of Clinical Pharmacology 3

Approximately 50% of patients prescribed either medication continue treatment for at least 12 months, a practice of doubtful efficacy in many cases, according to the World Health Organization 5
Both medications carry risk of dependence and withdrawal symptoms with sudden cessation, and increase risk of dangerous respiratory depression when combined with opioids, as warned by the CDC 5, 2

Somnolence is a prominent adverse effect of pregabalin, occurring alongside visual disturbances when newly started, as stated in the 2024 BMJ guidelines, which is relevant to the American College of Neurology 6, 7
The British Medical Journal guidelines note that both gabapentin and pregabalin cause dose-dependent sedation, with somnolence, dizziness, and impaired driving ability being major concerns, as per the guidelines from the National Institute for Health and Care Excellence 6, 7

Elderly patients with renal impairment require lower starting doses and slower titration of both gabapentin and pregabalin due to increased fall risk from dizziness and confusion, as recommended by the American Geriatrics Society 6, 7
Renal impairment mandates dose reduction for both medications to minimize toxicity and sedation risk, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6, 7

If pregabalin is used, the World Journal of Emergency Surgery recommends using the lowest effective dose, considering 75-150 mg rather than 300 mg, to minimize somnolence 8
Patients should be warned explicitly about visual disturbances and somnolence when newly started on pregabalin, as advised by the European Medicines Agency 6, 7